SEC Form 4 · accession 0001209191-19-004961
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Hirsch
Officer — Chief Financial Officer
Period of report
Jan 20, 2019
Accepted (ET)
Jan 23, 2019 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Jan 20, 2019 | M | 15,000 | — | A | 15,000 | D | |
| Common stock | Jan 22, 2019 | F | 4,555 | $52.82 | D | 10,445 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance share unitF1,F2 | — | Jan 20, 2019 | M | 15,000 | D | — | — | Common stock | 15,000 | 0 | D |
Explanation of responses
- F1Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- F2The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.